Modified organs and cells for xenotransplantation
AssigneeRBC Biotechnology, Inc.
InventorAlex Zhu
Life of this patent
Estimating the term…
Loading patent…
AssigneeRBC Biotechnology, Inc.
InventorAlex Zhu
Estimating the term…
It has been discovered that there are at least two significant antigens present on the cells of animal species such as pigs that elicit an immune or inflammatory response immediately upon implantation into humans or contact with human serum. The first is an α-galactosyl (Gal) epitope, for example, Galα(1->3)Galβ(1->4)GlcNac (linear B type 2) or Galα(1->3)Galβ(1->4)Glc (linear B type 6). The second is an N-glycolylneuraminic acid (NeuGc) structure. By eliminating these epitopes, preferably by genetically engineering the animal so that the epitope is either not produced or is greatly reduced, or by chemical or enzymatic treatment of the animal's cells to remove the epitopes, it is possible to produce organs, tissues and cells suitable for xenotransplantation into humans. Cells can be rendered even more compatible by genetically engineering the animal to express a human complement regulatory protein (inhibitor), such as CD59, on its cells, or to express an excess of a pig complement regulatory protein.
A method for making a nonhuman animal organ, tissue or cells for transplantation into a human comprising removing or reducing expression of N-glycolylneuraminic epitopes on the surface of the cells.
A method of treatment comprising transfusing a human in need thereof with the cells, tissues or organs produced by a method for making a nonhuman animal organ, tissue or cells for transplantation into a human comprising removing or reducing expression of N-glycolylneuraminic epitopes on the surface of the cells.
Organs, tissue or cells produced by a method for making a nonhuman animal organ, tissue or cells for transplantation into a human comprising removing or reducing expression of N-glycolylneuraminic epitopes on the surface of the cells.
A method for increasing the half-life of recombinant or non-human proteins comprising removing or reducing expression of NeuGc and/or Gal epitopes on the surface thereof.
Recombinant or non-human proteins having removed in whole or in part the NeuGc and/or Gal epitopes on the surface thereof.
Dependencies are inferred from the claim text.